2 weeks Ago By ABMN Staff
Cybin ( NYSE:CYBN – Get Free Report ) is one of 436 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Cybin to related businesses based on the strength of its valuation, institutional ownership, analyst recommendations, earnings, profitability, risk and dividends. Risk and Volatility Cybin has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500.
Comparatively, Cybin’s rivals have a beta of 1.27, indicating that their average stock price is 27% more volatile than the S&P 500. Institutional & Insider Ownership 17.
9% of Cybin shares are owned by institutional investors. Comparatively, 28.8% of shares of all “Biotechnology” companies are owned by institutional investors.
15.0% of Cybin shares are owned by company insiders. Comparatively, 26.
1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Analyst Ratings Cybin presently has a consensus price target of $50.
50, indicating a potential upside of 426.04%. As a group, “Biotechnology” companies have a potential upside of 19.
11%. Given Cybin’s stronger consensus rating and higher probable upside, analysts clearly believe Cybin is more favorable than its rivals. Profitability This table compares Cybin and its rivals’ net margins, return on equity and return on assets.
Earnings and Valuation This table compares Cybin and its rivals top-line revenue, earnings per share and valuation. Cybin’s rivals have higher revenue and earnings than Cybin. Cybin is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Summary Cybin rivals beat Cybin on 8 of the 13 factors compared. Cybin Company Profile ( Get Free Report ) Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.
The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers.
The company is headquartered in Toronto, Canada. Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter .
.
